GSK Restructures R&D Division Following Departure of Head of Research John Lepore

On September 18, according to foreign media fierce biotech reports, GSK's R&D department is undergoing a reshuffle following the departure of John Lepore, Senior Vice President and Head of R&D.

After John Lepore's departure, GSK divided its R&D department into three teams more closely aligned with the core therapeutic divisions: Respiratory and Immunology, Vaccines and Infectious Diseases, and Oncology. Senior Vice President and Global Head of Vaccines, Phil Dormitzer, will lead the Vaccines and Infectious Diseases R&D team; Senior Vice President and Global Head of Oncology Development, Hesham Abdullah, will lead the Oncology R&D team; and Kaivan Khavandi, newly joined GSK, will lead the reorganized Respiratory Immunology team.

A GSK spokesperson stated that as investment in R&D increases, the company’s top priority is to accelerate the delivery of its product pipeline. These three teams will focus on initial discovery and early clinical research, and if a project reaches Phase II clinical trials, it will be handed over to an independent internal team for further development.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account backend or send a message, and specify the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Highlights Preview

Online Live Streaming & Offline Salon

↑ Long press to scan the QR code and sign up for the event ↑